Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity ... cost alternative to the current injector pen formulation of Zepbound and are easier to produce.

and $549 for the 5-mg dose ($137.25 per vial), which the company noted was "in line with the Zepbound savings program for noncovered individuals." (The new direct single-dose prescriptions cannot ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

Zepbound (tirzepatide) is a prescription drug that’s used for weigh loss in certain adults. The drug comes as a liquid solution inside prefilled injection pens. Zepbound is not safe to use while ...

Eli Lilly’s Mounjaro was added to the FDA’s drug shortage database in 2022, while Zepbound was added this April. Eli Lilly did not immediately respond to a request for comment from Quartz.

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ...